Roche fined for hindering entry of generic cancer drugs
Romania’s Competition Council has fined F. Hoffmann-La Roche’s local subsidiary €12.8 million for abusing its dominance in multiple cancer treatment markets, but the drugmaker has accused the enforcer of acting in bad faith and ignoring evidence of its innocence.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.